Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 13501 - 13525 of 14518 in total

3-hydroxyisoxazole-4-carboxylic acid

Experimental

3'-Deazo-Thiamin Diphosphate

Experimental

Carpropamide

Experimental

4-Sulfonamide-[1-(4-Aminobutane)]Benzamide

Experimental

1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Experimental

(1R,2R)-N-(2-Aminoethyl)-2-{[(4-methoxyphenyl)sulfonyl]methyl}cyclohexanecarboxamide

Experimental

Cambendazole

Experimental
Vet approved

CG-200745

Cg200745 has been used in trials studying the treatment of Solid Tumour.
Investigational

IL15-NK Cell

Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Investigational
Matched Description: … In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor …

ATG-101

ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and …

(2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE

Experimental

[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID

Experimental

5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

Experimental

N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine

Experimental

4-(1H-IMIDAZOL-1-YL)PHENOL

Experimental

(5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE

Experimental

REP8839

REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational

CRx-401

CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … lipid profiles, and this dose has proven to be well tolerated in clinical trials. ... in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and …

MF268

Experimental

Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]

Experimental

6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE

Experimental

4-AMINO-2-TRIFLUOROMETHYL-5-HYDROXYMETHYLPYRIMIDINE PYROPHOSPHATE

Experimental

N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine

Experimental

2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE

Experimental

N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine

Experimental
Displaying drugs 13501 - 13525 of 14518 in total